Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
MWN-AI** Summary
Polyrizon Ltd. (Nasdaq: PLRZ), a pre-clinical-stage biotechnology company based in Raanana, Israel, has announced a significant development agreement with Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biopharmaceutical company. The focus of this collaboration is the development of a proprietary intranasal formulation of MEAI (5-methoxy-2-aminoindane), a non-hallucinogenic neuroplastogen candidate aimed at treating addiction-related and central nervous system (CNS) conditions.
The partnership capitalizes on Polyrizon's advanced intranasal delivery platform, designed to enhance therapeutic outcomes by improving nasal residence time, enabling targeted delivery, and optimizing patient usability. Polyrizon's intranasal administration approach offers potential advantages over traditional oral methods, such as bypassing first-pass metabolism, allowing for quicker absorption, and potentially lowering effective dosages. These factors make the intranasal delivery of MEAI a promising avenue as Clearmind advances its clinical development initiatives.
Tomer Izraeli, CEO of Polyrizon, expressed pride in collaborating with Clearmind, emphasizing that their proprietary technology could provide more efficient drug delivery and enhance the clinical pathway for MEAI. Polyrizon's expertise in creating medical device hydrogels that act as protective agents in the nasal cavity complements Clearmind's vision of delivering neuroplastogen-derived therapeutics to address significant health issues.
Both companies are committed to advancing their innovative therapeutic solutions. Polyrizon’s technology, including its Capture and Contain™ and Trap and Target™ hydrogel formulations, underlines their focus on enhancing drug delivery systems for improved patient outcomes. This strategic collaboration signifies Polyrizon’s growing role as a specialized partner in intranasal drug delivery development, adding potential value to Clearmind’s therapeutic approach.
MWN-AI** Analysis
Polyrizon Ltd. (Nasdaq: PLRZ) recently announced a significant partnership with Clearmind Medicine Inc. (Nasdaq: CMND) to develop an intranasal formulation of MEAI, a next-generation, non-hallucinogenic neuroplastogen intended for treating addiction and central nervous system conditions. This collaboration leverages Polyrizon's sophisticated intranasal delivery platform, known for its ability to enhance drug delivery efficiency, patient compliance, and formulation flexibility.
From a market perspective, this strategic partnership presents an intriguing investment opportunity. Polyrizon's advanced proprietary technology not only positions it as a leader in intranasal delivery systems but also indicates its growing role as a sought-after partner in the biotech landscape. Investors should take notice of the potential advantages of the MEAI intranasal solution, which could bypass first-pass metabolism, allowing more direct systemic access and potentially reducing effective dosage for patients.
As the clinical development of neuroplastogen-based therapeutics continues to grow, particularly in treating under-addressed issues like substance abuse, Polyrizon stands poised to benefit immensely from this trend. With Clearmind’s robust pipeline and intellectual property portfolio, alongside Polyrizon’s innovative delivery methods, this collaboration could lead to substantial advancements in treatment efficacy.
However, prospective investors must also consider the inherent risks associated with biotech investments, especially in early-stage companies, where success is contingent upon clinical trial outcomes and regulatory approvals. The volatility of the market and potential changes in the development landscape add another layer of risk.
In summary, while Polyrizon's collaboration marks a promising development in the biotech sector, investors should conduct comprehensive due diligence, weighing the growth potential against the accompanying risks. Staying informed on upcoming clinical milestones and market responses will be critical for investors looking to capitalize on this opportunity.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Collaboration aims to leverage Polyrizon’s advanced proprietary intranasal delivery platform to support clinical development of Clearmind’s drug candidate proprietary MEAI
Raanana, Israel, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has entered into a development agreement with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”), a clinical?stage biopharmaceutical company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems. Under this agreement, Polyrizon will develop a proprietary intranasal formulation of MEAI (5?methoxy?2?aminoindane), Clearmind’s proprietary, next-generation, non-hallucinogenic neuroplastogen drug candidate, intended for use in the treatment of addiction?related and other central?nervous?system (CNS) conditions.
The collaboration between companies holds both scientific and strategic rationale as the objective of the collaboration is to advance an intranasal MEAI formulation to support Clearmind’s future clinical development programs initiatives.
Polyrizon’s technology platforms are designed to enable:
- Enhanced nasal residence time, through specialized gel?like mechanisms
- Consistent and targeted delivery of active compounds
- Optimized patient usability
- Formulation flexibility tailored to the physicochemical profile of the API
Intranasal administration is widely studied as a delivery route with potential advantages over oral administration for certain disorders (or indications), particularly those intended for CNS activity. Potential advantages, to MEAI, include:
- Bypassing first?pass metabolism, which may allow more direct systemic access
- Potentially faster absorption, depending on compound characteristics
- Lowering effective dose
These factors collectively support the exploration of intranasal delivery for MEAI as Clearmind continues its development efforts.
Tomer Izraeli, Chief Executive Officer of Polyrizon, commented,: “We are proud to collaborate with Clearmind on the development of an intranasal formulation of MEAI. Our proprietary intranasal technology is designed to enable more targeted, efficient delivery, and we believe it may offer meaningful value as Clearmind advances MEAI through its clinical pathway. We believe that this agreement reflects Polyrizon’s growing role as a partner of choice for companies seeking specialized intranasal drug?delivery expertise.”
About Polyrizon
Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information, visit: https://www.clearmindmedicine.com
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses how the collaboration with Clearmind aims to leverage Polyrizon’s advanced proprietary intranasal delivery platform to support clinical development of Clearmind’s drug candidate proprietary MEAI, advancing an intranasal MEAI formulation to support Clearmind’s future clinical development programs initiatives and its belief that the collaboration with Clearmind reflects Polyrizon’s growing role as a partner of choice for companies seeking specialized intranasal drug?delivery expertise. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.
Contacts:
Michal Efraty
Investor Relations
FAQ**
How does the collaboration between Clearmind and Polyrizon Ltd. (PLRZ) enhance the potential clinical applications of the MEAI formulation in treating addiction-related CNS conditions?
What specific advantages does Polyrizon Ltd. (PLRZ)'s intranasal delivery platform offer over traditional oral administration in the context of MEAI's therapeutic efficacy?
Can you elaborate on the timeline and milestones Clearmind expects to achieve in clinical development with the support of Polyrizon Ltd. (PLRZ)?
What are the anticipated challenges in the clinical development of the MEAI formulation, and how does Polyrizon Ltd. (PLRZ) plan to address them during the collaboration?
**MWN-AI FAQ is based on asking OpenAI questions about Clearmind Medicine Inc. (NASDAQ: CMND).
NASDAQ: CMND
CMND Trading
-7.79% G/L:
$1.06 Last:
46,328 Volume:
$1.11 Open:
